Lineage restriction analyses in CHIP indicate myeloid bias for TET2 and multipotent stem cell origin for DNMT3A
Abstract
We analyzed DNA from polymorphonuclear (PMN) cells, monocytes, B cells, and T cells of 107 individuals with clonal hematopoiesis of indeterminate potential (CHIP) to perform lineage restriction analysis of different gene mutations. Three lineage categories were defined: myeloid (PMN with or without monocytes), myelolympho-B (myeloid and B cells), and multipotent (myeloid, B and T cells). Six individuals with aberrant patterns were excluded from analysis. Ninety-four had a single mutation (56 in DNMT3A , 24 in TET2 , 7 in other genes [ JAK2 , ASXL1 , CBL or TP53 ]). Fourteen had multiple mutations. The lineage restriction patterns of single DNMT3A - or TET2 -mutated individuals were different. The proportion of myeloid restricted mutations was higher for TET2 (54.2%, 13 of 24) than for DNMT3A (23.2%, 13 of 56) ( P TET2 individuals ( P TET2 mutation in the multipotent category in contrast to 35.7% (20 of 56) for DNMT3A ( P DNMT3A suggesting a time delay for extensive lineage clonal dominance. These distinctive features may be important in deciphering the transformation mechanisms of these frequent mutations.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
DNMT3A and TET2 mutations are most prevalent in myeloid cells for TET2 and show a multilineage distribution for DNMT3A-carrying clones.
“the most frequent mutations DNMT3A and TET2 mutations, are most prevalent in myeloid cells for TET2 and show a multilineage distribution for DNMT3A-carrying clones [30].”
From Clonal Hematopoiesis of Indeterminate Potential as an Emerging Interdisciplinary Risk Factor in Alzheimer’s Disease: Current Evidence and Future Directions (2026) · cites this paper as [30]
The downstream consequences of CHIP differ substantially between vascular and neurodegenerative environments, where shared clonal variants may promote deleterious systemic inflammation while simultaneously enhancing protective amyloid clearance within the brain.
“these findings reveal that the downstream consequences of CHIP differ substantially between vascular and neurodegenerative environments, where shared clonal variants may promote deleterious systemic inflammation while simultaneously enhancing protective amyloid clearance within the brain [30].”
From Clonal Hematopoiesis of Indeterminate Potential as an Emerging Interdisciplinary Risk Factor in Alzheimer’s Disease: Current Evidence and Future Directions (2026) · cites this paper as [30]
Cites
Age-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841 · see citing works
Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults
Young, A. L., Challen, G. A., Birmann, B. M., & Druley, T. E. (2016) · Nature Communications · doi:10.1038/ncomms12484 · Cited by 692 · see citing works
Nonrandom X-inactivation patterns in normal females: lyonization ratios vary with age
Busque, L., Mio, R., Mattioli, J., Brais, E., Blais, N., Lalonde, Y., Maragh, M., & Gilliland, D. (1996) · Blood · doi:10.1182/blood.v88.1.59.59 · Cited by 543 · see citing works
Self-citationBuscarlet, M., Provost, S., Zada, Y. F., Barhdadi, A., Bourgoin, V., Lépine, G., Mollica, L., Szuber, N., Dubé, M.-P., & Busque, L. (2017) · Blood · doi:10.1182/blood-2017-04-777029 · Cited by 383 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
The roles of DNA, RNA and histone methylation in ageing and cancer
Michalak, E. M., Burr, M. L., Bannister, A. J., & Dawson, M. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0143-1 · Cited by 549 · see citing works
Kopp, K., Silva, P., Damm, F., & Cosma, N. C. (2026) · Biomedicines · doi:10.3390/biomedicines14051012
- Authors
- Buscarlet, M., Provost, S., Zada, Y. F., Bourgoin, V., Mollica, L., Dubé, M.-P., & Busque, L.
- Affiliations
- Hôpital Maisonneuve-Rosemont (CA)
- Montreal Heart Institute (CA)
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2018-07-19
- Volume
- 132
- Issue
- 3
- Pages
- 277-280
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2803478601
- Cited by
- 146
- References
- 4
- Citations by year
- 2026: 15 · 2025: 12 · 2024: 22 · 2023: 18 · 2022: 17 · 2021: 19 · 2020: 27 · 2019: 13 · 2018: 3
- FWCI
- 11.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- TET2, DNMT3A, clonal hematopoiesis, CHIP, lineage restriction, myeloid bias, multipotent stem cells, clonal dominance, clonal evolution
- MeSH terms
- DNA Methyltransferase 3A, Aged, Aged, 80 and over, Cell Differentiation, DNA (Cytosine-5-)-Methyltransferases, DNA-Binding Proteins, Female, Humans, Male, Middle Aged, Models, Biological, Mutation, Proto-Oncogene Proteins, Biomarkers, Cell Lineage, Multipotent Stem Cells, Chromatin Immunoprecipitation, Dioxygenases, High-Throughput Nucleotide Sequencing, Clonal Evolution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review